Switching From Reference Adalimumab to Biosimilar Shows No Major Differences in Patients With RA, PsA
Biosimilars can be a more affordable and accessible treatment option for patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
Optimizing Patient Treatment Adherence in CML
A panelist discusses how pharmacists can significantly improve treatment adherence in chronic myeloid leukemia patients through regular patient touchpoints, adherence…
Guidelines vs. Real Life in mCRC: Success Isn’t ‘One Size Fits All’
Panelists discuss how endpoint prioritization in late-line metastatic colorectal cancer therapy differs between providers and patients, with pharmacists focusing primarily…
1056: Rapid administration of antiseizure medications
Show notes at pharmacyjoe.com/episode1056. In this episode, I’ll discuss the rapid administration of antiseizure medications. The post 1056: Rapid administration…
Oral SERDs in Breast Cancer: Imulnestrant and Elacestrant
Oral selective estrogen receptor degraders (SERDs) are a promising line of treatments for patients with breast cancer.
FDA Approves Updated COVID-19 Vaccines Targeting LP.8.1 For Older Adults, Those At-Risk
The FDA’s approvals follows new COVID-19 guidance announced by the commissioner of the agency in May 2025, focusing future approvals…
Orforglipron’s Success in Phase 3 Trial Triggers Regulatory Submissions for Obesity Treatment
Orforglipron is an effective treatment, leading to significant body weight reduction and improved glycemic control.
Neighborhood Marginalization Worsens Outcomes in Young Myocardial Infarction Survivors
Young adults who had experienced an acute myocardial infarction and lived in marginalized communities had increased risks of adverse events…